CBD is no more a drug than honey is, industry expert tells FDA science board

If CBD is to be regulated as a drug, then so should honey. That was one of the views put forward as industry members and the US Food and Drug Administration (FDA) butted heads at a meeting of the FDA Science Board public advisory committee.

Sibyl Swift, vice president for scientific and regulatory affairs of North Carolina-based company cbdMD, said foods such as honey were known to have biochemical and physiological effects on cells, tissues, and organs, otherwise known as pharmacological effects. She argued that honey has been found to cause pharmacological harm but is not questioned in the same way that CBD is.

Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization